Skip to main content
European Commission logo print header

The Sound of a Healthy Herd. Revolutionising the Care of Dairy Cattle with Pioneering Acoustic Technology

Project description

Improving cattle health with acoustic technology

Bovine mastitis is a persistent and inflammatory reaction of the udder tissue as a result of physical trauma or microorganisms infections. It is the most common disease in dairy cattle worldwide. Continued use of antibiotics weakens the health of cattle, decreasing milk production, eventually weakening cows that are removed from the herd. The EU-funded APT project has developed innovative non-invasive; antibiotics free therapies based on acoustic pulse technology. It has been used successfully for over 20 years in human healthcare treating inflammatory diseases. It now aims to develop the optimal solutions for bovine mastitis.

Objective

"Armenta Ltd, was established to address the most-costly disease affecting dairy farming today: Bovine Mastitis.
Mastitis is the most pressing disease affecting cows, however antibiotics are the only available option worldwide - close to 50% of antibiotics are used in food producing animals. The continued use of antibiotics in the treatment and prevention of infections of dairy cows has a direct effect on fostering Anti-Microbial Resistance (AMR), an urgent matter of particular public interest. The continued use of antibiotics also weakens the cow’s health, decreasing its milk production and eventually, weak cows are removed from the herd, causing high economic losses that can reach €2.4B per year in Europe alone. Armenta was therefore established to address these pressing economic effects, with a revolutionary way of using APT.
Armenta developed innovative non-invasive; antibiotics free therapies based on acoustic pulse technology (APT). APT has been used for over 20 years in human healthcare treating inflammatory diseases. Armenta employs experts in acoustic pulse treatment and engineering, mastitis researchers, ex-dairy farmers and dairy farming operation, bringing their skills and proficiency into developing the optimal solutions for bovine mastitis.
Armenta aims at becoming a leader in 1) fighting the spread of AMR 2) boosting the dairy economy giving €1.4B cash back to the EU farmers each year 3) increasing cow’s welfare and longevity. Moreover, it aims at being considered the #1 alternative to antibiotics, endorsed by leading international organization.
"

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-EIC-SMEInst-2018-2020-3

Funding Scheme

SME - SME instrument

Coordinator

ARMENTA LTD
Net EU contribution
€ 2 245 379,50
Address
5 hasharon st.
4427120 Kfar sava
Israel

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 962 305,50